NCT05177770Phase 2Terminated

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Study sponsor: Coherus Oncology, Inc. · CHRS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-04-05Actual
Enrollment · participants16Actual
Source updated2025-05-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview